Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / ADAP - Adaptimmune: Drug Approval Now Imminent?

ADAP - Adaptimmune: Drug Approval Now Imminent?

Adaptimmune Therapeutics plc

2024-02-02 12:49:37 ET

Summary

  • Adaptimmune's BLA for their T-cell therapy in soft tissue sarcomas has been accepted for review by the FDA.
  • The company's lead candidate, Afami-cel, has shown promising results in synovial sarcoma, with a PDUFA date set for August 4, 2024.
  • Adaptimmune's cash position is low, but expected milestone payments from their collaboration with Genentech may extend their cash runway.

Topline Summary and Update

For further details see:

Adaptimmune: Drug Approval Now Imminent?
Stock Information
Company Name: Adaptimmune Therapeutics plc
Stock Symbol: ADAP
Market: NASDAQ
Website: adaptimmune.com
Menu
ADAP ADAP Quote ADAP Short ADAP News ADAP Articles ADAP Message Board
Get ADAP Alerts

News, Short Squeeze, Breakout and More Instantly...